| Title： | Consensus of Chinese experts on the management of national medical insurance negotiation drug in medical institutions |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | Pharmacists, physicians, and other related medical personnel, as well as managers of health administration and medical security authorities in medical institutions of all levels and types |
| Evidence classification method： | The evidence sources of this expert consensus are mainly various research literatures. GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) method is adopted to evaluate the quality of the evidence system. Some evidence sources are mainly documents from relevant national departments, and the evidence is graded according to the Legislation Law. Since the literature evidence based on this expert consensus is mainly non-classical evidence, the type of evidence will be comprehensively considered in the evaluation process, and the quality evaluation tools for classical research evidence will not be used to evaluate the quality of evidence for non-classical evidence. |
| Development unit： | Precision Pharmacy Working Committee of Chinese Pharmacists Association |
| Registration time: | 2024-08-01 |
| Registration number： | PREPARE-2024CN098 |
| Purpose of the guideline: | This expert consensus is formulated based on relevant provisions of laws and regulations as well as the best available evidence, mainly focusing on the whole process of landing negotiated drugs in medical institutions. It highlights the current status of negotiated drug access and clinical application management in medical institutions. Centered on patients, it provides lean management measures and guiding suggestions to ensure the rational use of negotiated drugs in clinical practice, and achieves the lean management of the whole chain of negotiating drugs in medical institutions. |
